Viatris (VTRS) Non-Current Deferred Tax Liability (2019 - 2026)
Viatris (VTRS) posted quarterly Non-Current Deferred Tax Liability of $870.6 million for Q1 2026, down 19.58% year-over-year from $1.1 billion in Q1 2025, and down 2.4% quarter-over-quarter from $892.0 million in Q4 2025.
Viatris (VTRS) Non-Current Deferred Tax Liability (2019 - 2026) Analysis & Trends
Viatris' Non-Current Deferred Tax Liability history runs 8 years deep, the most recent figure standing at $870.6 million for Q1 2026.
- In Q1 2026, Non-Current Deferred Tax Liability fell 19.58% year-over-year to $870.6 million; the TTM figure through Mar 2026 stood at $870.6 million (down 19.58% YoY), while the FY2025 annual figure was $892.0 million, down 55.55% from the prior year.
- Non-Current Deferred Tax Liability for Q1 2026 stood at $870.6 million, down from $892.0 million in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $2.7 billion in Q1 2022, with the low at $870.6 million in Q1 2026.
- The 5-year median for Non-Current Deferred Tax Liability is $1.7 billion (2023), against an average of $1.8 billion.
- The sharpest annual moves came in 2024 and 2025: Non-Current Deferred Tax Liability advanced 15.62% in 2024, then slumped 55.55% in 2025.
- Viatris' Non-Current Deferred Tax Liability stood at $2.4 billion in 2022, then retreated by 28.63% to $1.7 billion in 2023, then gained by 15.62% to $2.0 billion in 2024, then plunged by 55.55% to $892.0 million in 2025, then declined by 2.4% to $870.6 million in 2026.
- Business Quant data shows VTRS's Non-Current Deferred Tax Liability at $870.6 million in Q1 2026, $892.0 million in Q4 2025, and $1.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Alkermes | 8.02 Bn | 7.37 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 802.80 Mn |
| Jun 30, 2026 | 802.80 Mn |
| Mar 31, 2026 | 870.60 Mn |
| Mar 31, 2026 | 870.60 Mn |
| Dec 31, 2025 | 892.00 Mn |
| Dec 31, 2025 | 892.00 Mn |
| Sep 30, 2025 | 1.03 Bn |
| Sep 30, 2025 | 1.03 Bn |
| Jun 30, 2025 | 1.08 Bn |
| Jun 30, 2025 | 1.08 Bn |
| Mar 31, 2025 | 1.08 Bn |
| Mar 31, 2025 | 1.08 Bn |
| Dec 31, 2024 | 2.01 Bn |
| Dec 31, 2024 | 2.01 Bn |
| Sep 30, 2024 | 1.28 Bn |
| Sep 30, 2024 | 1.28 Bn |
| Jun 30, 2024 | 1.57 Bn |
| Jun 30, 2024 | 1.57 Bn |
| Mar 31, 2024 | 1.67 Bn |
| Mar 31, 2024 | 1.67 Bn |